Fujii, Hironori
Ueda, Yukino
Hirose, Chiemi
Ohata, Koichi
Sekiya, Kumiko
Kitahora, Mika
Sadaka, Shiori
Yamamoto, Senri
Watanabe, Daichi
Kato-Hayashi, Hiroko
Iihara, Hirotoshi
Kobayashi, Ryo
Kaburaki, Miho
Matsuhashi, Nobuhisa
Takahashi, Takao
Makiyama, Akitaka
Yoshida, Kazuhiro
Hayashi, Hideki
Suzuki, Akio
Article History
Received: 28 December 2021
Accepted: 8 February 2022
First Online: 2 March 2022
Declarations
:
: This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval for the study was obtained from the ethics committees of Gifu Pharmaceutical University (Approval Number: 3–9) and Gifu University Graduate School of Medicine (Approval number: 2021–03).
: Not applicable.
: K. Yoshida has received honoraria for lectures from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly and Company, Yakult Honsha Co., Ltd., Merck Sharp & Dohme Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Johnson & Johnson Co., Ltd., Covidien Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., Asahi Kasei Co., Ltd., Tsumura Co., Ltd., EA Pharma Co., Ltd., Bayer Yakuhin Co., Ltd., Olympus Co., Ltd., Terumo Co., Ltd., Bristol-Myers Squibb Co., Ltd., Denka Co., Ltd., Teijin Co., Ltd., SBI Pharmaceuticals Co., Ltd., Intuitive Surgical Co., Ltd., Novartis Pharma K.K., and Pfizer Inc.; and research funding from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly and Company, Yakult Honsha Co., Ltd., Merck Sharp & Dohme Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Johnson & Johnson Co., Ltd., Covidien Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., Asahi Kasei Co., Ltd., Tsumura Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Co., Ltd., Toyama Chemical Co., Ltd., Kinetic Concepts Co., Ltd., Abbott Japan Co., Ltd., and Toray Industries, Co., Ltd. outside the submitted work.T. Takahashi has received honoraria for lectures from Takeda Pharmaceutical Co., Ltd.A. Makiyama has received honoraria for lectures from Eli Lilly and Company, Taiho Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd.The other authors have no conflicts of interest.